Full Breakdown
Federal Actions Target Pharmacy Benefit Managers to Lower Drug Prices
2/19/2026, 8:25:14 PM
Overview of the Core Event
Recent federal initiatives aim to enhance transparency in the operations of pharmacy benefit managers (PBMs), entities that play a crucial role in the U.S. prescription drug supply chain. These actions, driven by President Donald Trump’s administration, seek to address longstanding concerns regarding the opaque practices of PBMs, which have been accused of inflating drug prices and limiting competition.
Historical Context of PBMs
PBMs emerged in the 1960s to assist insurers and employers in managing prescription drug benefits. The Employee Retirement Income Security Act (ERISA) of 1974 facilitated their growth, allowing large employers to utilize their services. Over time, PBMs have consolidated, with the three largest—Express Scripts, CVS Caremark, and OptumRx—controlling nearly 80% of drug transactions in the U.S. This consolidation has raised questions about competition and pricing practices within the industry.
Key Developments in Regulation
In April 2025, President Trump issued an Executive Order titled “Lowering Drug Prices by Once Again Putting Americans First,” directing the Department of Labor to introduce a proposed rule aimed at increasing transparency in PBM operations. This rule mandates that PBMs disclose various forms of compensation, including direct payments from plans and rebates from drug manufacturers. The goal is to empower employers and plan sponsors to negotiate better deals, ultimately lowering drug prices for consumers.
Legislative Changes and Industry Response
In February 2026, Trump signed a bipartisan spending bill that included significant reforms for PBMs, marking the first major regulatory changes in decades. The new law prohibits PBMs from receiving compensation from Medicare Part D plans based on drug prices and mandates that they pass 100% of manufacturer rebates back to health plans. Critics within the PBM industry have expressed discontent, arguing that these reforms stem from lobbying efforts by drug manufacturers rather than sound policy.
Criticism and Opposition
Opponents of the reforms, including representatives from the Pharmaceutical Care Management Association, argue that the new regulations could lead to higher drug prices rather than the intended reductions. They contend that the reforms mischaracterize the role of PBMs in the drug pricing ecosystem, suggesting that the focus on transparency may overlook the complexities of drug pricing negotiations.
Conflicting Reports and Gaps
While the proposed rule and legislative changes aim to enhance transparency, there is skepticism about their effectiveness. Some experts, like Antonio Ciaccia, acknowledge the unprecedented nature of these reforms but caution that past attempts to regulate PBMs have often been circumvented. Additionally, ongoing lawsuits against major PBMs, including a recent settlement involving Express Scripts over insulin pricing, highlight the contentious nature of the industry and the challenges in achieving meaningful reform.
Conclusion and Future Implications
The federal government’s push to regulate PBMs represents a significant shift in the landscape of prescription drug pricing. By increasing transparency and accountability, these measures aim to foster competition and ultimately reduce costs for consumers. However, the effectiveness of these reforms remains to be seen, as the industry adapts to new regulations and ongoing legal challenges continue to unfold.
